- Home
- ARVN vs VTYX Comparison
ARVN vs VTYX Comparison
Compare ARVN & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARVN | VTYX |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 806.0M | 713.6M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ARVN | VTYX |
|---|---|---|
| Price | $12.16 | $9.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 5 |
| Target Price | ★ $17.89 | $14.60 |
| AVG Volume (30 Days) | 1.0M | ★ 1.7M |
| Earning Date | 02-10-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $312,300,000.00 | N/A |
| Revenue This Year | $11.17 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 93.86 | N/A |
| 52 Week Low | $5.90 | $0.78 |
| 52 Week High | $21.00 | $10.55 |
Technical Indicators
Market Signals| Indicator | ARVN | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 52.88 | 58.38 |
| Support Level | $11.86 | $7.59 |
| Resistance Level | $12.50 | $9.53 |
| Average True Range (ATR) | 0.53 | 0.52 |
| MACD | -0.12 | 0.04 |
| Stochastic Oscillator | 39.41 | 88.66 |
Price Performance
Historical ComparisonAbout ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.